Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer.

Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Abstract Text:

    teruhiko fujiiTeruhiko Fujii,goro yokoyamaGoro Yokoyama,hiroki takahashiHiroki Takahashi,roka namotoRoka Namoto,shino nakagawaShino Nakagawa,uhi tohUhi Toh,masayoshi kageMasayoshi Kage,kazuo shirouzuKazuo Shirouzu,michihiko kuwanoMichihiko Kuwano,

    We have investigated protein kinase C (PKC) signaling, a putative differentiation-related and metastasis suppressor gene Cap43/NDRG1/Drg-1, and Y-box binding protein-1 (YB-1) to identify new molecular targeting for breast cancer. PKC is a family of serine/threonine kinases that is involved in the regulation of cell growth. We have demonstrated that PKC caused G(1) arrest in a breast cancer cell line through a mechanism involving a PKC-ERK MAPK-JNK-Rb protein signaling pathway. We have also characterized a novel mechanism through which all-trans retinoic acid (ATRA) and antineoplaston, anticancer drug, caused cell growth inhibition in breast cancer cells through effects on intracellular pathways. ATRA decreased the expression of PKCalpha, as well as reduced ERK MAPK phosphorylation, and consequently caused G(1) arrest. Antineoplaston caused the down-regulation of PKCalpha protein expression, resulting in inhibition of ERK MAPK phosphorylation, with resultant inhibition of Rb phosphorylation leading to G(1) arrest. PKC signaling represents a promising target for development of novel therapeutic agents. Cap43 is known as N-myc downstream-regulated gene 1 (NDRG1). Treatment with estradiol (E(2)) significantly decreased the expression of Cap43 in ER-alpha-positive breast cancer cell lines. Co-administration of tamoxifen abrogated the E(2)-induced downregulation of Cap43 in ER-alpha-positive cell lines. These results suggested that Cap43 may hold the potential of being a molecular marker to determine the therapeutic efficacy of anti-estrogenic anticancer agents in breast cancer. YB-1 is a member of the cold shock domain protein family. The expression of nuclear YB-1 was correlated with HER2 positively in clinical specimens of human breast cancer. Immunostaining studies showed that nuclear YB-1 expression was an independent prognostic factor of overall survival. Expression of nuclear YB-1 played an essential role in acquirement of malignant characteristics through HER2-dependent pathways in breast cancer patients. PKC, Cap43 and YB-1 may be useful in new molecular-targeting diagnosis and therapeutics in breast cancer.

    Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Publishing Authors By Initials

    t fujiiT Fujii,g yokoyamaG Yokoyama,h takahashiH Takahashi,r namotoR Namoto,s nakagawaS Nakagawa,u tohU Toh,m kageM Kage,k shirouzuK Shirouzu,m kuwanoM Kuwano,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Breast cancer (Tokyo, Japan)

    VOLUME: 15

    Page Numbers: 73-8

    Journal Abbreviation: Breast Cancer

    ISSN: 1880-4233

    DAY: 28

    MONTH: 01

    YEAR: 2008

    Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 100888201

    Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer.

    AFFILIATION: Department of Surgery, Kurume University, Asahimachi 67, Fukuoka, 830-0011, Japan.

    Country: Japan

    Japan Research PublicationJapan Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Breast Cancer

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News